Skip to search formSkip to main contentSkip to account menu

baricitinib

Known as: 3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- 
An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

AzetidinesSulfonamides

Narrower (2)

INCB028050LY3009104
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Compositions and methods for treatment of vitiligo
Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be… 
2017
2017
FRI0124 Temporary interruptions of study drug during the baricitinib phase 3 rheumatoid arthritis program
Background Temporary interruption of RA therapy is common in clinical practice; therefore, rapid clearance and low immunogenicity… 
2017
2017
Baricitinib vs. Placebo or Adalimumab for Rheumatoid Arthritis
Compared to placebo and adalimumab, the addition of once-daily oral baricitinib produced significant clinical improvements in RA… 
2017
2017
Baricitinib en el tratamiento de la artritis reumatoide
Las proteinas cinasas desempenan un papel fundamental en las vias de senalizacion intracelular implicadas tanto en la inmunidad… 
2017
2017
Elevation of serum PCSK 9 concentrations and its correlation with C-reactive protein , but not atherogenic lipids in patients with systemic lupus erythematosus
Methods: Serum samples were obtained from 48 patients with RA and 48 healthy controls. The enzyme-linked immunosorbent assay… 
2017
2017
216. BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND…
Background: Baricitinib, an oral JAK1/JAK2 inhibitor, improves disease activity with an acceptable safety profile in patients… 
2016
2016
Novel synthetic method for baricitinib and intermediate thereof
The invention discloses a novel intermediate compound 5 of baricitinib. The compound 5 has stable properties, which is favorable… 
2016
2016
Baricitinib polymorph A and preparation method thereof
The invention provides a baricitinib polymorph A. The baricitinib polymorph A is characterized in that diffraction peaks are… 
2012
2012
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in…
2012
2012
12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying…